Delivery Order SPE2DB22D3301-SPE2DB25FY8EY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Everolimus 0.75 mg tablets (60-count) with a ceiling value of $6,624.37. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by August 11, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under a larger vehicle and carries no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Everolimus 1 mg tablets (60-count) with a ceiling value of $16,540.67. This firm fixed-price delivery order is not set-aside and represents a competitive award to the prime contractor. The contract is set to be completed by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Everolimus 5 mg tablets (30-count packages) with a ceiling value of $44,765.09. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 13, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Department's Medical Supply Chain awarded a $18,147.63 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Everolimus 10 mg tablets in quantities of 30. The contract was competitively awarded without set-aside restrictions under a firm fixed-price delivery order mechanism, with an ultimate completion date of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a prime pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Everolimus 2.5 mg tablets in unit dose packaging (28-count) with a ceiling value of $1,095.33. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $3,978.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count) under a firm fixed-price contract valued at $10,949.64. This delivery order, which is a child award under AmerisourceBergen's broader contract vehicle, represents a competitive award with no set-aside designation and is scheduled for completion by August 20, 2025. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Everolimus 5 mg tablets in a quantity of 30 units, valued at $5,193.76. This is a firm fixed price delivery order with no set-aside designation, representing a competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. The contract's ultimate completion...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60-count), with a contract ceiling value of $2,665.42. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $39,614.76 to AmerisourceBergen Drug Corp for the supply of Everolimus 10 mg tablets (30-count units). This firm fixed price contract, awarded on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY8EYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Everolimus 5 mg tablets in quantities of 30 units, with a ceiling value of $19,375.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on July 23, 2025, with performance being executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, fulfills a critical role in the federal medical supply chain, particularly for Department of Defense and veteran healthcare systems. The parent IDC enables the company to supply an extensive portfolio of pharmaceutical products across multiple therapeutic domains to support military healthcare programs worldwide. This specific delivery order for Everolimus, an immunosuppressant medication commonly used in transplant and oncology applications, represents a routine transaction within the company's ongoing relationship with DLA to ensure continuity of pharmaceutical supply to federal medical facilities and personnel.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.4k | 7/22/25 |